Table 4 COVID-19 vaccination status of 421 participants with persistent headache after COVID-19 in Latin America
From: New daily persistent headache after SARS-CoV-2 infection in Latin America: a cross-sectional study
Vaccination status | All (n = 421, 100%) | NDPH (n = 106, 25.2%) | Non-NDPH (n = 315, 74.8%) | p value |
|---|---|---|---|---|
Vaccinated against COVID-19 before headache onset, n (%) | 0.827a | |||
No | 167 (39.7) | 43 (40.6) | 124 (39.4) | |
Yes | 254 (60.3) | 63 (59.4) | 191 (60.6) | |
Type of vaccine, yes (%) | ||||
BBIBP-CorV/Sinopharm | 130 (51.2) | 28 (44.4) | 102 (53.4) | 0.217a |
Gam-COVID-Vac/Sputnik-V | 58 (22.8) | 9 (14.3) | 49 (25.7) | 0.062a |
BNT162b2/Pfizer-BioNTech | 36 (14.2) | 13 (20.6) | 23 (12) | 0.09a |
ChAdOx1-S/nCoV-19/AstraZeneca | 27 (10.6) | 12 (19) | 15 (7.9) | 0.012a |
CoronaVac/Sinovac | 16 (6.3) | 6 (9.5) | 10 (5.2) | 0.224a |
Janssen/Johnson & Johnson | 6 (2.4) | 3 (4.8) | 3 (1.6) | 0.164b |
CIGB-66/Abdala | 3 (1.2) | 2 (3.2) | 1 (0.5) | 0.153b |
mRNA-1273/Moderna | 2 (0.8) | 0 (0) | 2 (1) | 1b |
Ad5-nCoV/CanSino | 1 (0.4) | 0 (0) | 1 (0.5) | 1b |
Vaccination scheme, n (%) | 0.377a | |||
Incomplete (1 dose) | 37 (14.6) | 9 (14.3) | 28 (14.7) | |
Complete (2 doses) | 164 (64.6) | 37 (58.7) | 127 (66.5) | |
Complete + Booster (≥ 3 doses) | 53 (20.8) | 17 (27) | 36 (18.8) | |
Time from the last vaccination dose to headache onset, n (%) | 0.947a | |||
≤ 6 months | 213 (83.9) | 53 (84.1) | 160 (83.8) | |
> 6 months | 41 (16.1) | 10 (15.9) | 31 (16.2) |